Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Colorectal Disease
Published in: International Journal of Colorectal Disease 6/2006

01-09-2006 | Original Article

Down-regulation of interferon-γ parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study

Authors: V. Muratov, J. Lundahl, A. K. Ulfgren, K. Elvin, I. Fehrman, N. Ahlborg, Å. Öst, N. Hittel, A. Saniabadi, R. Löfberg

Published in: International Journal of Colorectal Disease | Issue 6/2006

Login to get access

Abstract

Background & aims

Pilot studies have indicated a therapeutic role for an apheresis device (Adacolumn) that selectively adsorbs leukocytes in patients with inflammatory bowel diseases. It may also exert immunoregulatory effects contributing to its clinical efficacy. This study aimed to correlate the clinical response to leukocyte apheresis with the expression of key cytokines in mucosal tissue, in peripheral leukocytes, and in plasma.

Methods

Ten patients (seven with Crohn’s disease and three with ulcerative colitis, median age: 31 years) with mild to moderately chronic activity were recruited to an open study. Patients were refractory to or had a relapse despite conventional treatment including azathioprine. Leukocyte apheresis was performed once a week for five consecutive weeks. Clinical efficacy was assessed on week 7 and after 12 months. Colonoscopy with multiple biopsies was performed at the start of the study and after 7 weeks for semiquantitative immunohistochemical analyses of cytokines. Cytokine levels in blood and the proportion of cytokine producing CD4+ and CD8+ lymphocytes were determined.

Results

The apheresis procedures were well tolerated and no major adverse events were encountered. The median clinical activity score decreased from 12 to 7 on week 7 (P=0.031, n=9) and to 4 after 12 months (P=0.004, n=9). Five patients were in clinical remission at the 12th month. Tissue interferon (IFN)-γ-positive T-cells decreased in clinical responders (P=0.027) after apheresis. In parallel, significantly lower levels of IFN-γ-producing lymphocytes were detected in peripheral blood. IFN-γ-positive cells in pretreatment biopsies completely disappeared or decreased in posttreatment biopsies sampled on week 7 in responders (P=0.027) and appeared to predict the maintenance of long-term remission or response after 12 months.

Conclusions

Leukocyte apheresis is a novel and safe nonpharmacological adjunct therapy that may prove useful in steroid refractory or dependent patients when conventional drugs have failed. Down-regulation of IFN-γ in mucosal biopsies and in peripheral leukocytes may be a predictive marker for sustained, long-term response.
Literature
1.
2.
Sandler RS, Loftus EV (2004) Epidemiology of inflammatory bowel diseases. In: Sartor RB, Sandborn WJ (eds) Kirsners’ Inflammatory bowel diseases. Saunders, Edinburgh, pp 245–262
3.
Ahmad T, Pesi C, Jewell D, Colombel JF (2004) Clinical relevance of advances in genetics and pharmacogenetics of IBD. Gastroenterol 126:1533–1549CrossRef
4.
Sartor RB (2004) Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics and prebiotics. Gastroenterol 126:1620–1633CrossRef
5.
Rachmilewitz D (1989) Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis. Br Med J 298:82–86 (on behalf of an international study group)CrossRef
6.
Hanauer SB (2004) Medical therapy of ulcerative colitis 2004. Gastroenterol 126:1582–1592CrossRef
7.
Egan LJ, Sandborn WJ (2004) Advances in the treatment of Crohn’s disease. Gastroenterol 126:1574–1581CrossRef
8.
Panaccione R, Fedorak RN (2003) Primer of current therapies in inflammatory bowel disease. In: Satsangi J et al (eds) Inflammatory bowel disease. Churchill Livingstone, London, pp 320–331
9.
van Dullemen HM, van Deventer SJ, Hommes DW, Bijil HA, Woody J (1995) Treatment of Crohn’s disease with anti-tumour necrosis factor chimeric monoclonal antibody (cA2). Gastroenterol 109:129–135CrossRef
10.
Lichtiger S, Present DH, Kornbluth A et al (1994) Cyclosporine A I severe ulcerative colitis refractory to steroid treatment. N Engl J Med 330:1841–1845PubMedCrossRef
11.
Loftus E, Sandborn W (2004) Balancing the risks and benefit of infliximab treatment of IBD. Gut 53:780–782PubMedCrossRef
12.
Siveke JT, Folwaczny (2004) Medical approaches and future options in chronic active ulcerative colitis. Int J Colorectal Dis 19:297–307PubMedCrossRef
13.
Rutgeerts PR, Asssche GV, Vermeire S (2004) Optimizing anti-TNF treatment in IBD. Gastroenterol 126:1593–1610CrossRef
14.
Cassatella MA (1995) The production of cytokines by polymorphonuclear neutrophils. Immunol Today 16:21–26PubMedCrossRef
15.
Nikolaus S, Bauditz J, Gionchetti P (1998) Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin-10 during intestinal inflammation. Gut 42:470–476PubMedCrossRef
16.
Saniabadi AR, Hanai H, Takeuchi K, Bjarnason I, Lofberg R (2003) Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial 7:48–59PubMedCrossRef
17.
D’Arrigo C, Candal-Couto JJ, Greer M, Veale DJ, Woof JM (1994) Human neutrophil Fc receptor mediated adhesion under flow: a hallow fiber model of intravascular arrest. Clin Exp Immunol 100:173–179CrossRef
18.
Hiraishi K, Takeda Y, Shiobara N, Shibusawa H, Jimma F, Kashiwagi N, Saniabadi AR, Adachi M (2003) Studies on the mechanisms of leukocyte adhesion to cellulose acetate beads: an in vitro model to assess the efficacy of cellulose acetate carrier-based granulocyte and monocyte adsorptive apheresis. Ther Apher Dial 7:334–340PubMedCrossRef
19.
Ohara M, Saniabadi AR, Hirata I, Kasukawa R (1997) Granulocytapheresis in the treatment of patients with rheumatoid arthritis. Artif Organs 21:989–994PubMedCrossRef
20.
Kashiwagi N, Hirata I, Kasukawa R (1998) A role for granulocyte and monocyte apheresis in the treatment of rheumatoid arthritis. Ther Apher 2:134–141PubMedCrossRef
21.
Shimoyama T, Sawada K, Hiwatashi N, Sawada T, Saniabadi AR (2001) Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apheresis 16:1–9PubMedCrossRef
22.
Hanai H, Watanabe F, Saniabadi A, Matsushita I, Takeuchi K, Iida T (2002) Therapeutic efficacy of granulocyte and monocyte adsorption apheresis in severe active ulcerative colitis. Dig Dis Sci 47:2349–2353PubMedCrossRef
23.
Matsui T, Nishimura T, Matake H, Ohta T, Sakurai T, Yao T (2003) Granulocytapheresis for Crohn’s Disease: a report on seven refractory patients. Am J Gastroenterol 511–512
24.
Törkvist L, Thorlacius H, Sjöqvist U et al (1999) Low molecular weight heparin as adjuvant therapy in active ulcerative colitis. Aliment Pharmacol Ther 13(10):1323–1328 (Oct)PubMedCrossRef
25.
Danielsson Å, Löfberg R, Salde L, Schiöler R, Suhr O, Willén R (1992) A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis and proctitis. Scand J Gastroenterol 27:9–12PubMedCrossRef
26.
Geboes K, Riddell RH, Öst Å, Jensfelt B, Persson T, Löfberg R (2000) A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 47:404–409PubMedCrossRef
27.
Källström E, Roscher I, Andreasson A, Back O, van Hage-Hamsten M (2002) Decreased frequency of intracellular IFN-gamma producing T cells in whole blood preparations from patients with atopic dermatitis. Exp Dermatol 11(6):556–563 (Dec)PubMedCrossRef
28.
Schreiber S (2003) Overview of medical treatment. In: Satsangi J et al (eds) Inflammatory bowel disease. Churchill Livingstone, London, pp 297–299
29.
Papadakis KA, Targan SR (2000) Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 51:289–298PubMedCrossRef
30.
31.
Lampinen M, Carlson M, Sangfelt P (2001) IL-5 and TNF-alpha participate in recruitment of eosinophils to intestinal mucosa in ulcerative colitis. Dig Dis Sci 46:2004–2009PubMedCrossRef
32.
McCarthy DA, Rampton DS, Liu Y-C (1991) Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clin Exp Immunol 86:489–493PubMedCrossRef
33.
Mahida YR (2000) The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis 6:21–33PubMedCrossRef
34.
Meuret G, Bitzi A, Hammer B (1978) Macrophage turnover in Crohn’s disease and ulcerative colitis. Gastroenterol 74:501–503
35.
Rugtveit J, Brandtzaeg P, Halstensen TS, Fausa O, Scott H (1994) Increased macrophage subsets in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes. Gut 35:669–674PubMedCrossRef
36.
Brannigan AE, O’Connell PR, Hurley H (2000) Neutrophil apoptosis is delayed in patients with inflammatory bowel disease. Shock 13:361–366PubMed
37.
Tibble JA, Sigthorsson G, Bridger D, Fagerhol MK, Bjarnason I (2000) Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterol 119:15–22CrossRef
38.
Hanai H, Watanabe F, Takeuchi K, Saniabadi A, Bjarnason I (2003) Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective uncontrolled pilot study. Clin Gastroenterol Hepatol 1:28–35PubMedCrossRef
39.
Lee, A, Whyte M, Haslett C (1993) Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators. J Leukoc Biol 54:283–288PubMed
40.
Kashiwagi N, Saniabadi A, Shimoyama T (2002) Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci 47:1334–1341PubMedCrossRef
41.
Tsukada Y, Nakamura T, Iimura M, Iizuka BE, Hayashi N (2002) Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytapheresis. Am J Gastroenterol 97(11):2820–2828 (Nov)PubMedCrossRef
42.
Sawada K, Ohnishi K, Kosaka T, Chikano S, Yokota Y, Egashira A, Izava H, Yamamura M, Amano K, Satomi M, Shimoyama T (1997) Leucocytopheresis with leukocyte removal filter as new therapy for ulcerative colitis. Ther Apher 1(3):207–211 (Aug)PubMedCrossRef
43.
Liu Z, Geboes K, Colpaert S, D’Haens GR, Rutgeerts P, Ceuppens JL (2000) IL-15 is highly expressed in inflammatory bowel disease and regulates local T cell-dependent cytokine production. J Immunol 164(7):3608–3615 (Apr 1)PubMed
44.
Autschbach F, Giese T, Gassler N, Sido B, Heuschen G, Heuschen U, Zuna I, Schulz P, Weckauf H, Berger I, Otto HF, Meuer SC (2002) Cytokine/chemokine messenger-RNA expression profiles in ulcerative colitis and Crohn’s disease. Virchows Arch 441:500–513PubMedCrossRef
45.
Rosenstiel P, Fantini M, Brautigam K, Kuhbacher T, Waetzig GH, Seegert D, Schreiber S (2003) TNF-α and IFN-γ regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells. Gastroenterol 124:1001–1009CrossRef
46.
Panes J (2001) Inflammatory bowel disease: pathogenesis and targets for therapeutic interventions. Acta Physiol Scand. 173:159–165PubMedCrossRef
Metadata
Title
Down-regulation of interferon-γ parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study
Authors
V. Muratov
J. Lundahl
A. K. Ulfgren
K. Elvin
I. Fehrman
N. Ahlborg
Å. Öst
N. Hittel
A. Saniabadi
R. Löfberg
Publication date
01-09-2006
Publisher
Springer-Verlag
Published in
International Journal of Colorectal Disease / Issue 6/2006
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-005-0069-2

Other articles of this Issue 6/2006

International Journal of Colorectal Disease 6/2006 Go to the issue

Original Article

Functional changes after physiotherapy in fecal incontinence

Original Article

Increasing anastomosis safety and preventing abdominal adhesion formation by the use of polypeptides in the rat

Original Article

Cost–benefit analysis of screening colonoscopy in 40- to 50-year-old first-degree relatives of patients with colorectal cancer

Original Article

Isolation and cultivation of neuronal precursor cells from the developing human enteric nervous system as a tool for cell therapy in dysganglionosis

Original Article

Reduction of miss rates of colonic adenomas by zoom chromoendoscopy

Original Article

The duration of postoperative ileus after elective colectomy is correlated to surgical specialization